drugset / Trial / NCT07080775
The Safety and Tolerability of XS411CN Injection in Treatment of Primary Parkinson's Disease
Phase 1
Recruiting
12 enrolled
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
Beijing Tiantan Hospital · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This Phase I clinical trial is designed to evaluate the safety, tolerability of a single dose of XS411 (derived dopaminergic neural progenitor cell injection) in patients with primary Parkinson's disease
Timeline
- Start
- 2025-08-05
- Primary completion
- 2026-04-30
- Completion
- 2029-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | XS411CN | Cell therapy | 4.5e+06 cells | Other |
| Subject | XS411CN | Cell therapy | 9e+06 cells | Other |
| Subject | XS411CN | Cell therapy | 1.8e+07 cells | Other |